Co-Diagnostics, Inc. Ships Product to India for Validation Study
Shipment includes 10,000 tests to be sold as Research Use Only by Joint Venture
The validation study for the most recent iteration of the Company’s test
for tuberculosis will be conducted at the
The shipment also contained other
This press release contains forward-looking statements.Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.Readers of this press release are cautioned not to place undue reliance on any forward-looking statements.The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Co-Diagnostics Investor Relations
Lytham Partners, LLC
Joe Diaz, Robert Blum and Joe Dorame